CHICAGO -- The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Adding rusfertide to standard care can reduce the need for phlebotomy and improve symptoms in patients with polycythemia vera who require frequent phlebotomies, data suggest.

Expelled, homeless, and ready to quit – this first-generation college student's path to her social work degree at Ferris ...

In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a ...

Rusfertide (Protagonist Therapeutics/Takeda Pharmaceuticals) — administered as a once-weekly subcutaneous injection — also ...

PAVE recently hosted a graduation ceremony for PAVE East Texas students who have received their GED diploma as well as ...

Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus ...

The first half of this year has been riddled with market volatility and geopolitical tension. But 2025’s American Society of ...

Mid and South Essex NHS Foundation Trust has signed a 15-year contract with SYNLAB for the delivery of a ‘hub and spoke’ ...

Beales announced in February that its last remaining department store would close at the end of May but said the NHS hub ...

Rion Aesthetics, an internationally recognized regenerative aesthetics company, today announced that the U.S. Food and Drug Administration (FDA) has allowed an Investigational New Drug (IND) ...